A Pharmacokinetic Study of CVX-096 (PF-04856883) in Healthy Volunteers

Pfizer

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Biological: PF-04856883

Study type: Interventional

Funder types: Industry

Identifiers

NCT01637285

B1111005

Details and patient eligibility

About

The purpose of the study is to further evaluate the PK characteristics of PF-04856883.

Enrollment: 49 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Exclusion criteria

Trial design

49 participants in 4 patient groups

PF-04856883 Treatment Arm 1

Experimental group

Treatment:

Biological: PF-04856883

Biological: PF-04856883

Biological: PF-04856883

Biological: PF-04856883

PF-04856883 Treatment Arm 2

Experimental group

Treatment:

Biological: PF-04856883

Biological: PF-04856883

Biological: PF-04856883

Biological: PF-04856883

PF-04856883 Treatment Arm 3

Experimental group

Treatment:

Biological: PF-04856883

Biological: PF-04856883

Biological: PF-04856883

Biological: PF-04856883

PF-04856883 Treatment Arm 4

Experimental group

Treatment:

Biological: PF-04856883

Biological: PF-04856883

Biological: PF-04856883

Biological: PF-04856883